• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

USDA provides conditional license for the Canine Parvovirus Monoclonal Antibody

May 2, 2023
Caitlin McCafferty, Editor

This brand-new treatment from Elanco is the first and only approved therapeutic solution proven to treat canine parvovirus

Elanco Animal Health Incorporated announced it has received conditional license from the United States Department of Agriculture (USDA) for its Canine Parvovirus Monoclonal Antibody. This historical approval marks the first, and currently only, approved therapeutic solution to treat canine parvovirus and the first monoclonal antibody for Elanco.

“Today’s announcement is a game changer for pet owners and veterinarians,” said Kristin Zersen, DVM, DACVECC, assistant professor of small animal emergency and critical care at Colorado State University Veterinary Teaching Hospital, in an organizational release.1

“Parvovirus is an unpredictable disease that causes significant strain on pet owners and is labor intensive and stressful for shelters and veterinary clinic staff. It’s life-changing and industry-defining to be able to offer a proven solution to canine parvovirus that limits the need for hospitalization, reducing the impact this disease has on hundreds of thousands of dogs each year,' added Zersen, who recently presented a continuing education session about treatments for canine parovirus at the Directions in Veterinary Medicine symposium in Arlington, Virginia.

This new treatment will provide a less intensive and more effective solution compared to targeting the virus with a single dose efficacy and a strong safety profile in healthy dogs. According to the release,1 during the treatment efficacy study, Canine Parvovirus Monoclonal Antibody was proven to be effective in decreasing mortality associated with parvovirus. Within the study, the treated dogs also showed signs of faster times to resolutions of the most-adverse effect of parvovirus, including vomiting.

“Elanco is proud to bring to the market this first-in-class treatment that will help save puppy's lives, while alleviating the emotional and financial burden of both pet owners and veterinary care teams,” said Jeff Simmons, president, and CEO, Elanco.

Advertisement

“We’re excited to bring our first monoclonal antibody treatment to market, reinforcing Elanco’s commitment to pioneer new tools in spaces where there aren’t existing options. We’re committed to helping the world’s pets live longer, healthier lives because we believe making life better for our pets makes life better,” he concluded.1

The Canine Parvovirus Monoclonal Antibody, pending individual state's approval, is set to ship in the coming weeks and will provide canine Parvovirus resources and education to pet parents, shelter owners, and veterinarians.

Reference

Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus. News releasee. Elanco Animal Health Incorporated. May 2, 2023. Accessed May 2, 2023. https://www.businesswire.com/news/home/20230427005591/en/Elanco-Announces-Breakthrough-Treatment-for-Deadly-Canine-Parvovirus

Related Content:

Clinical
Alternate therapies for pain management
Alternate therapies for pain management
Diagnostics for a thoracic trauma patient
Diagnostics for a thoracic trauma patient
Managing pain in the postoperative patient
Managing pain in the postoperative patient

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement